Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.

Name: Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.
Published: 2022
License: Public Domain

Pfizer · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

coronavirus-disease-2019-covid-19

biological availability, coronavirus disease 2019 (covid-19), severe acute respiratory syndrome coronavirus 2 (sars-cov-2), nirmatrelvir, paxlovid, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Relative Bioavailability Study of Nirmatrelvir/Ritonavir Oral Powder Relative to the Commercial Tablets and Estimation of the Effect of Food on Bioavailability of the Nirmatrelvir/Ritonavir Oral Powder in Healthy Participants.

Related documents